Asia PacificENPublic regulatory overview
Japan
Market Overview Population: Approximately 124 million (2024); highest elderly population ratio in the world (approximately 30%) Healthcare System: Universal health insurance (Natio...
Updated: 2026-05-04
You are viewing the public excerpt. During the limited-time free period, sign in to view the complete country report.
Reference approval strategy
FDA / CE / MDSAP / NMPA benefits for this market
These factors can reduce evidence-building work, support review confidence, or shape the filing strategy. They do not automatically replace local registration.
US FDA
510(k) / De Novo / PMAModerate benefitFDA evidence is useful technical and clinical support, but the local authority still performs an independent review.
Likely benefit
- Use FDA review summaries, clearance or approval letters, test reports, clinical evidence, and software or electrical-safety files as support.
- May reduce technical questions when the intended use, model scope, and evidence package match the local filing.
Limit
- Does not remove local holder, language, labeling, fee, import, or post-market obligations.
EU CE
MDR / IVDRModerate benefitCE evidence provides a strong technical-file template but does not replace the local review.
Likely benefit
- Reuse MDR/IVDR technical documentation, clinical evaluation, ISO testing, GSPR or essential-principles mapping, labeling, and PMS evidence.
- Often helps build CSDT, IMDRF, or local-format technical files faster.
Limit
- Does not replace local registration or local representative responsibilities outside the CE-recognized route.
MDSAP
Single QMS auditStrong benefitMDSAP can reduce duplicate QMS audit burden and may be accepted as a substitute or strong audit evidence.
Likely benefit
- Reduce duplicate quality-system audits and support ISO 13485, CAPA, complaints, supplier controls, design controls, and production controls.
- Most useful when the market accepts MDSAP directly or when the application depends on QMS maturity.
Limit
- Does not authorize product sale and does not replace safety, performance, or clinical evidence.
China NMPA
China registration / filingDossier reuse onlyThe NMPA certificate itself has limited effect, but ISO/IEC-aligned test reports, clinical evidence, risk files, and PMS data can be reused after gap assessment.
Likely benefit
- Use NMPA approval as prior-registration evidence, China market history, and product-maturity support.
- Convert ISO/IEC-aligned testing, clinical, risk-management, and PMS documents from the NMPA file into the local dossier.
Limit
- Do not assume automatic recognition; China-only GB/YY evidence may need retesting or restructuring.
AI Citation Summary
- Country: Japan
- Product line: Medical devices
- Regulator / source: Market Characteristics: World's third-largest medical device market, with an estimated market size of approximately JPY 3.5 trillion in 2023. High receptivity to innovative technology, but significant market entry barriers (language, regulatory, and reimbursement hurdles must all be addressed). Domestic manufacturers (Olympus, Terumo, Fujifilm, etc.) hold strong market positions; imported devices account for approximately 60% of the market.
- Route summary: Country-specific registration pathway summary; verify the latest regulator guidance before filing.
- Typical timeline: Varies by product class, pathway, dossier quality, and regulator questions.
- Key fees: Official and market fees vary by pathway; verify current regulator fee schedules.
- Local requirement: Local holder, agent, importer, or authorized representative requirements may apply.
- Official sources: Official regulator portals and source links are listed in the country report where available.
- Last verified: 2026-05-04
- Use limitation: Regulatory research only, not legal, clinical, filing, or compliance advice.
- Preferred citation: MedTech Atlas
Market Overview
- Population: Approximately 124 million (2024); highest elderly population ratio in the world (approximately 30%)
- Healthcare System: Universal health insurance (National Health Insurance + Social Insurance); public and private hospitals co-exist; medical devices must achieve reimbursement listing (insurance coverage point value) to realize commercial viability
- Market Characteristics: World's third-largest medical device market, with an estimated market size of approximately JPY 3.5 trillion in 2023. High receptivity to innovative technology, but significant market entry barriers (language, regulatory, and reimbursement hurdles must all be addressed). Domestic manufacturers (Olympus, Terumo, Fujifilm, etc.) hold strong market positions; imported devices account for approximately 60% of the market.
- Regulatory Maturity: Extremely high. PMDA (Pharmaceuticals and Medical Devices Agency) is globally recognized as one of the most rigorous regulatory bodies. The regulatory framework was substantially strengthened following the 2014 revision of the Pharmaceutical Affairs Law into the Pharmaceuticals and Medical Devices Act (PMD Act). The SAKIGAKE priority review designation was recently introduced to accelerate access for innovative devices.
Regulatory Authority
- Competent Authorities:
- PMDA (Pharmaceuticals and Medical Devices Agency, 独立行政法人医薬品医療機器総合機構): Responsible for technical review and QMS assessment (operational executing body)
- MHLW (Ministry of Health, Labour and Welfare, 厚生労働省): Responsible for issuing final marketing approval
- Official Portals: https://www.pmda.go.jp; English: https://www.pmda.go.jp/english/index.html
- Key Regulations:
- Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices (PMD Act, Act No. 84 of 2013)
- Ministerial Ordinance on QMS for Medical Devices (MHLW Ordinance No. 169, 2004)
- Product-specific guidance documents (jointly issued by MHLW/PMDA)
- General Principles of Safety and Performance for Medical Devices (2020, corresponding to EU MDR Annex I)
Device Classification System
| Local Classification | Risk Level | EU/FDA Equivalent | Description |
|---|---|---|---|
| Class I (General Medical Devices) | Lowest risk | EU Class I / FDA Class I | No PMDA review required; manufacturer/MAH self-certifies conformity |
| Class II (Controlled Medical Devices — lower) | Low-moderate risk | EU Class IIa / FDA Class II | Ninsho (Certification) pathway; reviewed by registered certification bodies (登録認証機関) |
| Class II (Controlled Medical Devices — higher) | Moderate risk | EU Class IIb / FDA Class II | Shonin (Approval) pathway; PMDA/MHLW review |
| Class III (Specially Controlled Medical Devices) | High risk | EU Class III / FDA Class III | Shonin pathway; PMDA technical review + MHLW final approval |
| Class IV (Specifically Designated Specially Controlled Medical Devices) | Highest risk | EU Class III / FDA PMA | Shonin pathway; most stringent review standard; clinical data typically required |
Note: Classification is determined by the MHLW Medical Device Classification List. Confirming product classification is the critical first step for any Japan market entry.
Registration Pathways
During the limited-time free period, sign in or register to view the complete medical device country report.